Biofrontera Inc. announced preliminary unaudited revenue results for the fourth quarter ended December 31, 2025, expecting revenues between $17.0 million and $17.5 million.
The fourth quarter results represent the highest quarterly revenue in the company's history, with year-over-year growth of 35% to 39%, mainly driven by the sales execution of Ameluz ®.
Full-year 2025 revenues are also expected to show double-digit growth of 11% to 13%.
Record Revenues
Preliminary fourth quarter revenues between $17.0 million and $17.5 million, marking a significant 35% year-over-year growth.
Sales Performance
Strong sales execution of Ameluz ® driving the impressive year-over-year growth of 35% to 39%.
Strategic Growth
Anticipated double-digit revenue growth of 11% to 13% for full-year 2025 showcases the company's strategic progress.
- The company's successful fourth quarter performance and revenue growth reflect strong execution across its business segments.
- Customer adoption and engagement remained robust, supporting record quarterly revenue performance and validating the strategic approach of Biofrontera Inc.
- The recent transformational transaction with Biofrontera AG is expected to enhance the company's gross margin profile and strengthen its financial foundation for sustainable growth into 2026.
Biofrontera Inc.'s robust performance in the fourth quarter of 2025, driven by sales execution and strategic initiatives, sets a positive trajectory for sustained growth in the coming year.